Skip to main content

TriSalus Life Sciences, Inc.

Qualité des données : 100%
Également cotée sous TLSIW NASDAQ
TLSI
NASDAQ Manufacturing Measuring & Analyzing Instruments
4,49 €
0,00 € (0,00%)
6 months return
Momentum
Neutral
Net margin
-86,88%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)53,41%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-73,98%
Net Margin-86,88%
Op. Margin-59,68%

Sécurité

Debt / Equity
N/A
Current Ratio3,05
Interest Coverage-4,86

Valorisation

PE (TTM|NTM)
-6,65 | -17,96
En dessous de la moyenne du secteur (-1,50)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -18,93 M
Capital efficient — spends only 2,03% of revenue on capex

Price History

Tendances Financières

Objectif de Cours des Analystes

5 analystes
Buy
+104.9%
upside to target
Actuel
4,49 €
Consensus Target
9,20 €
7,00 €
Bas
11,00 €
Haut
Prévisions
P/E Prévisionnel
-17,96
BPA Prévisionnel
-0,25 €
CA Est.
80,81 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,16 € · Rev Est: 10,44 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,27 € -0,23 € -0,87 € -0,05 €
Estimate -0,20 € -0,22 € -0,17 € -0,13 € -0,16 € -0,11 €
Surprise -34,74% -2,80% -425,70% +61,46%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 53,41% Revenue Growth (3Y) 56,18%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -86,88%
Revenue (TTM) 45,15 M Net Income (TTM) -39,23 M
ROE N/A ROA -100,87%
Gross Margin 84,57% Operating Margin -59,68%
Net Margin -86,88% Free Cash Flow (TTM) -18,93 M
ROIC -73,98% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3,05
Debt / Equity N/A Current Ratio 3,05
Interest Coverage -4,86 Asset Turnover 1,16
Working Capital 22,42 M Tangible Book Value -26,73 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -6,65 · EV/EBITDA: N/A
P/E Ratio -6,65 Forward P/E -17,96
P/B Ratio N/A P/S Ratio 5,78
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 3,23 Fwd Earnings Yield N/A
FCF Yield -7,25%
Market Cap 261,01 M Enterprise Value 271,09 M

Per Share

EPS: -1,84 · FCF/Share: -0,31
EPS (Diluted TTM) -1,84 Revenue / Share 0,74
FCF / Share -0,31 OCF / Share -0,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 48,26% · CapEx/Rev: 2,03%
CapEx / Revenue 2,03% FCF Conversion 48,26%
SBC-Adj. FCF -27,25 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 45,15 M 29,43 M 18,51 M
Net Income -39,23 M -30,05 M -59,04 M 5,54 M 4,77 M
EPS (Diluted) -1,84 -1,31 -6,73
Gross Profit 38,19 M 25,33 M 15,91 M
Operating Income -26,95 M -36,17 M -54,15 M -2,75 M -3,04 M
EBITDA
R&D Expenses 14,97 M 17,69 M 29,51 M
SG&A Expenses
D&A 626 000,0 744 000,0 702 000,0
Interest Expense 5,54 M 3,09 M 16 000,0
Income Tax 7 000,0 6 000,0 9 000,0 570 854,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 35,33 M 23,97 M 25,73 M 20,19 M 252,01 M
Total Liabilities 69,19 M 49,87 M 51,66 M 13,65 M 23,50 M
Shareholders' Equity -33,86 M -25,89 M -25,94 M -13,27 M -21,48 M
Total Debt 33,05 M 22,08 M
Cash & Equivalents 20,44 M 8,53 M 11,78 M 153 563,0 1,33 M
Current Assets 32,24 M 20,67 M 20,86 M 359 892,0 2,01 M
Current Liabilities 11,50 M 10,23 M 14,69 M 2,50 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -6,7 -1,5
P/B 1,6
ROE % -54,5
Net Margin % -86,9 -41,5
Rev Growth 5Y % 1,8
D/E 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,37% weight
VVICX VVICX
0,01% weight
IRSIX IRSIX
0,01% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight